A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy

The purpose of this study was to determine if use of a Gonadotropin releasing hormone (GnRH) antagonist, Ganirelix (Antagon), can improve pregnancy rates during superovulation with recombinant follicle-stimulating hormone (rFSH) followed by intrauterine insemination (IUI). This was a multicenter, pr...

Full description

Saved in:
Bibliographic Details
Published in:American journal of obstetrics and gynecology 2004-08, Vol.191 (2), p.648-651
Main Authors: Stan Williams, R., Hillard, Jessica B., De Vane, Gary, Yeko, Tim, Kipersztok, Simon, Rhoton-Vlasak, Alice, Sistrom, Chris
Format: Article
Language:English
Subjects:
Adult
Antagon
Drug Therapy, Combination
Female
Follicle Stimulating Hormone, Human - therapeutic use
Ganirelix
GnRH antagonists
Gonadotropin-Releasing Hormone - analogs & derivatives
Gonadotropin-Releasing Hormone - antagonists & inhibitors
Gonadotropin-Releasing Hormone - therapeutic use
Humans
Infertility
Infertility, Female - therapy
Insemination, Artificial - methods
Pregnancy
Pregnancy Outcome
Pregnancy Rate
Superovulation
Superovulation/intrauterine insemination
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to determine if use of a Gonadotropin releasing hormone (GnRH) antagonist, Ganirelix (Antagon), can improve pregnancy rates during superovulation with recombinant follicle-stimulating hormone (rFSH) followed by intrauterine insemination (IUI). This was a multicenter, prospective, randomized, open-label, assessor-blind, controlled trial of females (n=54), ages 18 to 39 undergoing superovulation/IUI with up to 4 cycles of superovulation/IUI without Ganirelix (n=66), or up to 4 cycles of superovulation/IUI with the addition of Ganirelix (n=52). No statistically significant difference in clinical pregnancy rates per cycle initiated was found for patients in the treatment or control group (12% vs 7%, P=.29). Other variables assessed, including endometrial thickness, size of follicles, peak serum estradiol levels, mid-lutea progesterone levels, and total vials of rFSH used also showed no statistically significant difference. Superovulation/IUI cycles using Ganirelix produce similar pregnancy rates when compared with cycles not using a GnRH antagonist, although there is a trend towards better pregnancy rates in cycles with Ganirelix.
ISSN:0002-9378
1097-6868
DOI:10.1016/j.ajog.2004.06.072